0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 15, Issue 2 (2023)
3 2023, 15(2): 191-198 |
Back to browse issues page
History
Received: 2023/02/14 | Accepted: 2023/04/16 | Published: 2023/06/5
Received: 2023/02/14 | Accepted: 2023/04/16 | Published: 2023/06/5
How to cite this article
Al-Saadi Z, Al-Aswad F, Sheaheed N. Oral Opportunistic Bacteria in Multiple Sclerosis with Different Treatment Modalities. 3 2023; 15 (2) :191-198
URL: http://ijwph.daneshafarand.org/article-3-85525-en.html
URL: http://ijwph.daneshafarand.org/article-3-85525-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Ministry of Health and Environment, Baghdad, Iraq
2- Department of Oral Medicine, College of Dentistry, Baghdad University, Baghdad, Iraq
3- Neurology Division Baghdad Teaching Hospital Medical City, Baghdad, Iraq
2- Department of Oral Medicine, College of Dentistry, Baghdad University, Baghdad, Iraq
3- Neurology Division Baghdad Teaching Hospital Medical City, Baghdad, Iraq
Abstract (2177 Views)
Aims: Multiple sclerosis is a chronic demyelinating disease that is considered an autoimmune disorder affecting the central nervous system. This study aimed to investigate the pathogenic changes in the natural flora of the mouth in MS patient during different treatment modalities and compare them with healthy individuals.
Materials & Methods: 120 patients were volunteered and divided into four groups of 30 people: 1) patients with MS taking Natalizumab or Tysabri, 2) patients with MS taking Betaferon, 3) naive MS patients without medications, 4) healthy individuals (control). The changes in oral bacteria (Staphylococcus aureus, Porphyromonas gingivalis, and Bacteroides fragilis) were investigate using real time-PCR.
Findings: The prevalence of S. aureus was significantly higher in the Naive MS group (p=0.016), Betaferon group (p=0.001), and Tysabri group (p=0.0001) compared to the healthy group, as well as in Tysabri group compared to the Naive MS group (p=0.005). The prevalence of P. gingivalis was significantly higher in the Betaferon group (p=0.002) and Tysabri group (p=0.0001) compared to the healthy group, as well as in Tysabri group compared to the Naive MS group (p=0.020). The prevalence of B. fragilis was significantly higher in the Naive MS group (p=0.008), Betaferon group (p=0.015), and Tysabri group (p=0.008) compared to the healthy group.
Conclusion: Oral bacteria are involved in MS development. Furthermore, MS patients are more susceptible to periodontal disease due to high P. gingivalis presence, and these patients need to receive extra care to prevent periodontal disease.
Materials & Methods: 120 patients were volunteered and divided into four groups of 30 people: 1) patients with MS taking Natalizumab or Tysabri, 2) patients with MS taking Betaferon, 3) naive MS patients without medications, 4) healthy individuals (control). The changes in oral bacteria (Staphylococcus aureus, Porphyromonas gingivalis, and Bacteroides fragilis) were investigate using real time-PCR.
Findings: The prevalence of S. aureus was significantly higher in the Naive MS group (p=0.016), Betaferon group (p=0.001), and Tysabri group (p=0.0001) compared to the healthy group, as well as in Tysabri group compared to the Naive MS group (p=0.005). The prevalence of P. gingivalis was significantly higher in the Betaferon group (p=0.002) and Tysabri group (p=0.0001) compared to the healthy group, as well as in Tysabri group compared to the Naive MS group (p=0.020). The prevalence of B. fragilis was significantly higher in the Naive MS group (p=0.008), Betaferon group (p=0.015), and Tysabri group (p=0.008) compared to the healthy group.
Conclusion: Oral bacteria are involved in MS development. Furthermore, MS patients are more susceptible to periodontal disease due to high P. gingivalis presence, and these patients need to receive extra care to prevent periodontal disease.